Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 3/20 | 0.56 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.56 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.55 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.46 |
| ▸ | PHGDH | O43175 | 2/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | MPO | P05164 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10275021 | 0.81 | CYP11B1 (0.57) | CYP11B1CYP11B2HSD11B1PDE10APHGDH | |
| SCHEMBL27549688 | 0.79 | CYP11B1 (0.56) | CYP11B1CYP11B2HSD11B1PDE10APHGDH | |
| SCHEMBL15635313 | 0.79 | CYP11B1 (0.57) | CYP11B1CYP11B2HSD11B1PDE10APHGDH | |
| SCHEMBL10246572 | 0.78 | CYP11B1 (0.55) | CYP11B1CYP11B2HSD11B1PDE10AMPO | |
| SCHEMBL10190913 | 0.77 | CYP11B1 (0.54) | CYP11B1CYP11B2HSD11B1PDE10APHGDH | |
| SCHEMBL17069344 | 0.77 | CYP11B1 (0.54) | CYP11B1CYP11B2HSD11B1PDE10APHGDH | |
| SCHEMBL8037981 | 0.75 | IDO1 (0.45) | CYP11B1CYP11B2HSD11B1PDE10APHGDH | |
| SCHEMBL13098202 | 0.74 | CYP11B1 (0.51) | CYP11B1CYP11B2HSD11B1PDE10AMAPT | |
| SCHEMBL4133477 | 0.74 | MAPT (0.55) | CYP11B1CYP11B2HSD11B1PHGDHBRD4 | |
| SCHEMBL13285586 | 0.71 | CYP11B1 (0.43) | CYP11B1CYP11B2HSD11B1PDE10APHGDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080242661-A1 | Novel compounds useful for the treatment of degenerative & inflammatory diseases | GALAPAGOS NV (BE) | 2008-10-02 | — | — | US | disclosed |
| WO-2008071650-A2 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | GALAPAGOS N.V. (BE) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242661-A1 | Novel compounds useful for the treatment of degenerative & inflammatory diseases | PDE4A, PDE7B, PDE4B | CYP11B1 1609/4885CYP11B2 2164/4885HSD11B1 652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.